Neurocrine Biosciences (NASDAQ:NBIX) CEO Kyle Gano Sells 36,400 Shares

by · The Markets Daily

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) CEO Kyle Gano sold 36,400 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the transaction, the chief executive officer directly owned 140,407 shares in the company, valued at approximately $18,632,008.90. The trade was a 20.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Kyle Gano also recently made the following trade(s):

  • On Tuesday, November 4th, Kyle Gano sold 300 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $141.97, for a total value of $42,591.00.

Neurocrine Biosciences Price Performance

Shares of NBIX stock traded up $2.15 during mid-day trading on Tuesday, hitting $134.54. 1,056,021 shares of the stock traded hands, compared to its average volume of 910,032. Neurocrine Biosciences, Inc. has a 52-week low of $84.23 and a 52-week high of $160.18. The stock has a market cap of $13.41 billion, a P/E ratio of 32.19, a P/E/G ratio of 0.65 and a beta of 0.28. The stock’s fifty day moving average is $144.15 and its two-hundred day moving average is $140.11.

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.59. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The business had revenue of $794.90 million for the quarter, compared to analyst estimates of $746.61 million. During the same quarter in the previous year, the firm earned $1.81 earnings per share. The company’s revenue was up 27.8% on a year-over-year basis. As a group, equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. AlTi Global Inc. lifted its stake in Neurocrine Biosciences by 1.0% during the 3rd quarter. AlTi Global Inc. now owns 6,828 shares of the company’s stock worth $959,000 after acquiring an additional 70 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in shares of Neurocrine Biosciences by 0.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 11,112 shares of the company’s stock worth $1,560,000 after purchasing an additional 77 shares in the last quarter. Perigon Wealth Management LLC lifted its position in shares of Neurocrine Biosciences by 3.1% during the fourth quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock worth $367,000 after purchasing an additional 78 shares in the last quarter. Diametric Capital LP boosted its stake in shares of Neurocrine Biosciences by 2.6% in the second quarter. Diametric Capital LP now owns 3,244 shares of the company’s stock valued at $408,000 after purchasing an additional 81 shares during the period. Finally, Signaturefd LLC grew its holdings in shares of Neurocrine Biosciences by 4.5% in the fourth quarter. Signaturefd LLC now owns 1,925 shares of the company’s stock valued at $273,000 after purchasing an additional 83 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on NBIX shares. UBS Group raised their price objective on shares of Neurocrine Biosciences from $188.00 to $195.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Morgan Stanley restated an “equal weight” rating and set a $175.00 price target (up previously from $173.00) on shares of Neurocrine Biosciences in a research report on Thursday, January 8th. TD Cowen upped their price objective on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Mizuho increased their target price on shares of Neurocrine Biosciences from $146.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, December 12th. Finally, Wall Street Zen raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $175.10.

View Our Latest Stock Analysis on NBIX

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

Featured Stories